Guidelines for treatment of ulcerative colitis in children

This paper introduces the guidelines for treatment of ulcerative colitis in children, created by the working group of the Japanese Society for Pediatric Gastroenterology, Hepatology and Nutrition (Chair: Yuichiro Yamashiro) and the Japanese Society for Pediatric Inflammatory Bowel Disease (IBD) (Chair: Akio Kobayashi). The ideas of the working group, with regard to the fundamental differences in medical treatment between children and adults, included: (1) for children, intensive medical treatment including appropriate systemic management is important during the acute phase of illness. (2) Treatment with steroids, which can cause growth disturbances, should not be continued for long periods of time. (3) Pulsed steroid therapy, selective removal of blood cells, and intravenous infusion of cyclosporin should be included in the therapeutic option for severe and fluminant cases.     

青黛散抗溃疡性结肠炎的作用研究

目的：探讨青黛散抗实验性溃疡性结肠炎的作用。方法：采用三硝基苯磺酸法制备大鼠溃疡性结肠炎模型，HE染色制作病理切片，对其抗实验性溃疡性结肠炎作用进行评价。结果：病理组织学检查表明青黛散有效改善了溃疡性结肠炎。结论：青黛散可有效对抗实验性结肠性溃疡炎。     

中药内外合治溃疡性结肠炎62例临床观察

[目的]观察中药内服配合灌肠治疗慢性溃疡性结肠炎的疗效。[方法]内服自拟健脾补肾汤配合清热燥湿解毒中药保留灌肠。[结果]62例中痊愈28例,占45·16%;好转27例,占43·55%;无效7例,占11·29%。总有效率为88·71%。[结论]中药内服配合灌肠治疗慢性溃疡性结肠炎的疗效确切,能加速溃疡面愈合并可促进和调整机体的免疫功能。     

吴茱萸次碱对小鼠溃疡性肠炎的治疗作用

目的:观察吴茱萸次碱治疗小鼠急性结肠炎的药效及对豚鼠肠道平滑肌运动的影响。方法:2,4-二硝基氯苯(DNCB)／乙醇灌肠制作小鼠急性结肠炎模型,经口给予吴茱萸次碱10、30、100 mg·kg-1,观察吴茱萸次碱对小鼠腹泻,组织形态损伤,结肠组织PGE2含量、MPO活力以及对乙酰胆碱、组胺作用下豚鼠离体肠管收缩运动的影响。结果:DNCB诱发结肠炎后,小鼠出现腹泻、充血、溃疡、肠壁增厚等变化。经口给予吴茱萸次碱后,可以显著改善小鼠的腹泻、组织损伤,并且能够降低结肠组织中MPO活性和PGE2的含量,对乙酰胆碱及组胺作用下豚鼠离体肠管收缩亦表现出显著的对抗作用。结论:吴茱萸次碱可以抑制炎性浸润、渗出和组织增生,减轻结肠黏膜的病理损害和抑制肠道平滑肌运动,对实验性动物急性结肠炎有较好的治疗作用。     

白头翁汤灌肠治疗溃疡性结肠炎患者的疗效及对T细胞亚群的影响

目的 观察白头翁汤灌肠治疗溃疡性结肠炎（UC）的疗效及对患者T细胞亚群的影响。方法 将我院2014年1月-2018年3月收治的124例UC患者随机分为对照组和观察组,2组均给予美沙拉嗪治疗,观察组另给予白头翁汤灌肠治疗。30 d后对比2组患者治疗有效率、肠镜评分、住院时间、UC活动度、T细胞亚群变化、不良反应发生率。结果 治疗30 d时,观察组治疗有效率（93.5%）明显高于对照组（72.6%）, P <0.05;观察组住院时间明显低于对照组（ P <0.05）;观察组DAI评分明显低于对照组（ P <0.05）;2组外周血中CD3+与CD8+均出现下降趋势,而CD4+与CD4+/CD8+均出现上升趋势,且观察组变化幅度明显大于对照组（ P <0.05）;观察组不良反应发生率为9.7%,对照组不良反应发生率为8.1%,差异不明显（ P >0.05）。结论 白头翁汤灌肠能够有效提高UC疗效,降低患者UC活动指数及住院时间,同时改善患者免疫功能,值得临床进一步推广应用。      

益阳汤结合益生菌及美沙拉嗪治疗溃疡性肠炎的临床分析

目的观察益阳汤结合益生菌、美沙拉嗪治疗溃疡性肠炎的临床疗效。方法对我院2015年8月~2016年10月期间所收治的136例溃疡性肠炎患者的临床资料进行回顾性分析,按照患者治疗方式的不同将其分为研究组与对照组,每组68例,对照组患者应用美沙拉嗪与益生菌联合治疗,研究组在此基础上加用益阳汤治疗,对比分析两组患者的临床疗效、用药时间、症状消失时间和不良反应发生情况,并对两组患者的炎症因子水平进行比较。结果研究组患者的临床总有效率(94.12%)明显高于对照组(82.35%),不良反应发生率(4.41%)低于对照组(20.59%),研究组治疗后的各项炎症因子水平也均优于对照组,且研究组用药时间[(9.52±2.18)d]与症状消失时间[(5.01±1.12)d]均短于对照组[(14.89±2.03)d、(9.23±1.56)d],差异有统计学意义(P0.05)。结论益阳汤结合益生菌、美沙拉嗪治疗溃疡性肠炎的临床效果远高于单纯应用西药治疗的效果,中西医结合治疗手段能够有效改善患者的临床症状,缩短患者的用药时间,且具有不良反应少的优势,值得临床应用。     

耳穴贴压治疗溃疡性结肠炎精神心理症状疗效观察

目的：耳穴贴压治疗溃疡性结肠炎精神心理症状的疗效观察。方法：将50例病例随机分为两组,分别采用常规治疗护理措施、耳穴贴压配合常规治疗护理措施的方法。结果 ：经治疗1个疗程后,常规治疗组（对照组）总有效率为68%;耳穴贴压组（干预组）总有效率为84%。结论：干扰组的疗效优于对照组,且具有统计学意义（P〈0.05）。     

A pharmacokinetic comparison of anrukinzumab,an anti- IL-13 monoclonal antibody,among healthy volunteers,asthma and ulcerative colitis patients

AimsAnrukinzumab is an anti-IL13 monoclonal antibody. The goals of this study are to characterize the pharmacokinetics of anrukinzumab in healthy volunteers and different disease states and to identify covariates.MethodsA population pharmacokinetic (PK) model was developed in NONMEM, using data from five clinical studies including healthy volunteers, asthma and ulcerative colitis (UC) patients. Different dosing regimens including different routes of administration were also included in the data.ResultsThe PK of anrukinzumab were described by a two compartment model with first order absorption and elimination. The population estimates (relative standard error) of the volumes of distribution in the central (V_c) and peripheral (V_p) compartments were 3.8 (4.6%) and 2.2 l (8.7%), respectively. In non-UC patients, the population estimate of the systemic clearance (CL) and inter-compartmental CL was 0.00732 l h^–1 (4.9%) and 0.0224 l h^–1 (15.4%). For subcutaneous administration, the absorption rate constant was 0.012 h^–1 (6.6%) and bioavailability was nearly 100% in healthy and mild to moderate asthma patients. Both V and CL increased with body weight. CL (but not V) decreased with increasing baseline albumin concentrations. UC patients had an increased CL of 72.3% (10.5%), after correction for differences in body weight and albumin. Moderate to severe asthma patients had decreased bioavailability compared with other populations.ConclusionsAnrukinzumab''s PK behave like a typical antibody. UC patients were identified to have a faster CL of anrukinzumab than healthy volunteers and asthma patients. This finding suggests a higher dose level may be required for this population.